Longitudinal follow-up of patients with double duct dilatation following endoscopic ultrasound

Hussain Amin Aaron On Raneem Albazaz Leeds Teaching Hospitals NHS Trust



- **Double duct dilatation (DDD)** refers to dilatation of both the common bile duct (CBD) and pancreatic duct (PD)
- It can be a sign of underlying **pancreaticobiliary malignancy**
- The follow-up of patients with DDD after initial assessment with endoscopic ultrasound (EUS) lacks consensus
- This study conducted a longitudinal review of patients with DDD following index EUS that did not show malignancy

Aims

Identify the **prevalence** of malignant pancreaticobiliary pathology in patients with DDD after negative index EUS

Identify other potential predictors of pathology from patient characteristics and risk factors

Methods

- Retrospective analysis
- Tertiary care centre
- Patients with DDD on **EUS** between **2015** and **2021**
- Review of: imaging reports / procedure reports / clinical notes / clinic letters
- Definitions of duct dilatation
 - CBD≥8mm
 - PD≥4mm

Methods

Baseline characteristics

- Age
- Sex
- Clinical features at presentation
 - Jaundice
 - Biliary pain
 - Weight loss
 - LFTs
 - CA19-9

Results


• **97** patients referred for EUS following DDD on cross-sectional imaging with no visible mass

• Following negative index EUS, pancreatic adenocarcinoma was subsequently identified in 3%

 In 2% this was via re-investigation of new clinical findings (no follow-up investigations performed prior to presentation with new clinical features)



 Patients with malignancy had at least one of biliary pain / weight loss / jaundice



Results: Follow-up period

- Median follow-up period was 37 months (range 2-85 months)
- Time from index EUS to malignant diagnoses were 26 days, 98 days, and 35 months

Baseline characteristics

Presenting symptoms:

- Biliary pain (57%)
- Abnormal LFTs (44%)
 - 18% of these also had jaundice
- Weight loss (28%)
- Jaundice (12%)

Other risk factors:

- Opioid use (35%)
- Previous cholecystectomy (25)
- Previously diagnosed chronic pancreatitis (8%)
- Previous ERCP (6%)

Results

Benign pathology identified:

- Benign ampullary stenosis (30%)
- Benign papillary fibrosis (9%)
- Microlithiasis (9%)
- IPMN (6%)
- Chronic pancreatitis (4%)
- Benign hypertrophy (3%)
- Choledocholithiasis (3%)
- SOD type 1 (2%)


3% of patients had subsequent malignant diagnosis during follow-up period

- pancreatic duct adenocarcinoma (2%)
- adenocarcinoma of the ampulla of Vater (1%)

Case A

- Presented with new onset jaundice and abnormal LFTs
- Bili 111 ALT 314 ALP 504
- Background: prostate cancer treated with SABR radiotherapy
- No mass or metastatic disease on cross-sectional imaging
- EUS showed DDD, diagnosed with gallstones, microlithiasis
- Jaundice did not resolve after ERCP and had surveillance via monitoring of LFTs
- Developed secondary cholecystitis requiring percutaneous drainage
- Ongoing symptoms → repeat EUS ampullary biopsies diagnosis adenocarcinoma within 26 days of index EUS


Case A



EUS and endoscopic views of abnormal ampulla after patient represented with symptoms


Case B

- Referred via GP under 2 week wait with unexplained weight loss, reduced appetite, recurrent nausea, change in bowel habit, PR bleed
- Cross-sectional imaging and subsequent EUS both suggested chronic pancreatitis
- Re-presented within 98 days with a 3 week history of **pruritus** and **jaundice** with deranged LFTs, repeat CT abdomen showed progressive changes concerning of a **mass lesion**
- Diagnosed with adenocarcinoma of the pancreatic head



Case C

- Incidental finding of DDD on cross-sectional imaging found on CT thorax for work-up of longstanding cough
- Index EUS showed benign papillary stenosis
- Managed conservatively as asymptomatic and discharged without further follow-up
- Re-presented **34 months** later with upper abdominal pain
- CT abdomen at this time showed T3N1M1 adenocarcinoma of the pancreas with hepatic metastasis



Discussion

- DDD is a concerning sign for underlying pancreaticobiliary malignancy
- Health service **increasingly dependent** on cross-sectional imaging with increasing number of incidental findings of DDD
- For patients with no obvious mass at index EUS (making malignancy less likely) - lack of guidance on evaluation and monitoring



- The likelihood of malignant pancreaticobiliary pathology following isolated DDD and negative index EUS is **low**
- Most cases are due to **benign** disease
- Low threshold for reassessment is advised for new clinical or biochemical findings

Areas for further research

- Test ways to help establish a calculatable risk based on risk factors in patients with DDD on imaging
- Future research could support this study with a multi-centre or nationwide cohort study with a larger sample size

Conclusion



Headline finding of **3%** of patients in this study with DDD developing malignant pancreaticobiliary pathology in the follow-up period

Low threshold needed for reinvestigation if new clinical / biochemical findings

References

- Niknejad M. Double duct sign: Radiology reference article [Internet]. Radiopaedia Blog. Radiopaedia.org; 2022 [cited 2022Nov23]. Available from: https://radiopaedia.org/articles/doubleduct-sign?lang=gb
- Yadav P, Lal H. Double duct sign. Abdom Radiol (NY). 2017 Apr 1;42(4):1283-4.
- Pancreatic cancer incidence statistics [Internet]. Cancer Research UK. 2022 [cited 2022Nov22]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statisticsby-cancer-type/pancreatic-cancer/incidence#heading-Zero
- Lyon PC, Murchison AG, Chen M, Wise R, Barge T, Nazir SA. A bump in the night: a 15-year retrospective analysis of urgent inpatient and emergency CT reporting out of hours in a tertiary referral centre. Clinical Radiology. 2022 Nov 1;77(11):810-22.
- Booth TC, Najim R, Petkova H. Incidental findings discovered during imaging: implications for general practice. British Journal of General Practice. 2016 Jul 1;66(648):346-7.